Terms: = Kidney tumors AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Treatment
18 results:
1. The prognostic significance of cdk6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract] [Full Text] [Related]
2. AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent/p53-dependent pathway.
Peng BY; Singh AK; Chan CH; Deng YH; Li PY; Su CW; Wu CY; Deng WP
BMC Cancer; 2023 Jan; 23(1):1. PubMed ID: 36597025
[TBL] [Abstract] [Full Text] [Related]
3. Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
Parmar A; Ghosh S; Sahgal A; Lalani AA; Hansen AR; Reaume MN; Wood L; Basappa NS; Heng DYC; Graham J; Kollmannsberger C; Soulières D; Breau RH; Tanguay S; Kapoor A; Pouliot F; Bjarnason GA
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1763. PubMed ID: 36517084
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.
Sager RA; Backe SJ; Ahanin E; Smith G; Nsouli I; Woodford MR; Bratslavsky G; Bourboulia D; Mollapour M
Nat Rev Urol; 2022 May; 19(5):305-320. PubMed ID: 35264774
[TBL] [Abstract] [Full Text] [Related]
5. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract] [Full Text] [Related]
6. Esculetin inhibits proliferation, migration, and invasion of clear cell renal cell carcinoma cells.
Duan J; Shi J; Ma X; Xuan Y; Li P; Wang H; Fan Y; Gong H; Wang L; Pang Y; Pang S; Yan Y
Biomed Pharmacother; 2020 May; 125():110031. PubMed ID: 32164951
[TBL] [Abstract] [Full Text] [Related]
7. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid tumors.
Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
[TBL] [Abstract] [Full Text] [Related]
8.
Pan H; Hong Y; Yu B; Li L; Zhang X
Cancer Biother Radiopharm; 2019 Jun; 34(5):334-341. PubMed ID: 30844301
[No Abstract] [Full Text] [Related]
9. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
[TBL] [Abstract] [Full Text] [Related]
10. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract] [Full Text] [Related]
11. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
[TBL] [Abstract] [Full Text] [Related]
12. Anti-proliferative potential of Glucosamine in renal cancer cells via inducing cell cycle arrest at G0/G1 phase.
Wang LS; Chen SJ; Zhang JF; Liu MN; Zheng JH; Yao XD
BMC Urol; 2017 May; 17(1):38. PubMed ID: 28558682
[TBL] [Abstract] [Full Text] [Related]
13. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
[TBL] [Abstract] [Full Text] [Related]
14. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract] [Full Text] [Related]
15. [Selective expansion of human natural killer cells].
Peng BG; Liang LJ; He Q; Li J; Lu MD
Ai Zheng; 2005 Oct; 24(10):1287-9. PubMed ID: 16219151
[TBL] [Abstract] [Full Text] [Related]
16. Renal haemodynamics, sodium and water reabsorption during continuous intravenous infusion of recombinant interleukin-2.
Geertsen PF; von der Maase H; Olsen NV; Fogh-Andersen N; Nielsen SL; Leyssac PP
Clin Sci (Lond); 1998 Jul; 95(1):73-81. PubMed ID: 9662488
[TBL] [Abstract] [Full Text] [Related]
17. Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.
Li SR; Yang Q; Wandl E; Pirker W; Virgolini I
Br J Cancer; 1993 Oct; 68(4):695-701. PubMed ID: 7691143
[TBL] [Abstract] [Full Text] [Related]
18. Adverse reactions to intravenous contrast media in patients treated with interleukin-2.
Shulman KL; Thompson JA; Benyunes MC; Winter TC; Fefer A
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):208-12. PubMed ID: 8471595
[TBL] [Abstract] [Full Text] [Related]
